Peptide Drug

DRAVP ID DRAVPc055

Name Nelfinavir

Sequence Not available

Molecular Formula C32H45N3O4S

Condition/Disease HIV Infection

Group Approved

Type Synthetic peptide

Description Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.

Active sequence/Structure

DrugBank Accession Number DB00220

Pubchem ID 64143

CHEMBL ID CHEMBL584

UNII HO3OGH5D7I

CAS 159989-64-7

Reference 9397180 36466430 33372574

NCT Number	Study Title	Condition/Disease	Status	Phase	Sponsor
NCT00246610	Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy	HIV infection	Completed	Phase 4	Pfizer
NCT00028067	A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor	HIV infection	Completed	Phase 3	Bristol-Myers Squibb

NCT Number

Study Title

Condition/Disease

Status

Phase

Sponsor

NCT00246610

Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy

HIV infection

Completed

Phase 4

Pfizer

NCT00028067

A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor

HIV infection

Completed

Phase 3

Bristol-Myers Squibb